Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses

被引:10
|
作者
Tsuchida, Hiroshi [1 ]
Takahashi, Sakiko [1 ]
Nosaka, Emi [1 ]
Mukaiyama, Osamu [2 ]
Yamashita, Makoto [3 ]
Morimoto, Kiyoshi [1 ]
机构
[1] Daiichi Sankyo Co Ltd, Biol Res Labs 3, Edogawa Ku, Tokyo 1348630, Japan
[2] Daiichi Sankyo Co Ltd, Global Project Management Dept, Tokyo 1348630, Japan
[3] Daiichi Sankyo Co Ltd, Biol Res Labs 4, Tokyo 1348630, Japan
关键词
CS-003; neurokinin; tachykinin; triple neurokinin receptor antagonist; capsaicin; cough;
D O I
10.1016/j.ejphar.2008.02.056
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Neurokinins are known to induce neurogenic inflammation related to respiratory diseases, though there is little information on triple neurokinin receptor antagonists. The pharmacological properties of the novel triple neurokinin 1, 2 and 3 receptor antagonist [1-{2-[(2R)-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoy1) morpholin-2-yl]ethyl}spiro[benzo[c]thiophene-1(3H),4'-piperidine]-(2S)-oxide hydrochloride] (CS-003) were evaluated in this study. The binding affinities of CS-003 were evaluated with human and guinea pig neurokinin receptors. As well, the in vivo antagonism of CS-003 against exogenous neurokinins and effects on capsaicin-induced and citric acid-induced responses were investigated in guinea pigs. CS-003 exhibited high affinities for human neurokinin 1, neurokinin 2 and neurokinin 3 receptors with K-i values (mean S.E.M.) of 2.3 +/- 0.52,0.54 +/- 0.11 and 0.74 +/- 0.17 nM, respectively, and for the guinea pig receptors with Ki values of 5.2 +/- 1.4, 0.47 +/- 0.075 and 0.71 +/- 0.27 nM, respectively. Competitive antagonism was indicated in a Schild analysis of substance P, neurokinin A- and neurokinin B-induced inositol phosphate formation with pA(2) values of 8.7,9.4 and 9.5, respectively. CS-003 inhibited substance P-induced tracheal vascular hyperpermeability, neurokinin A- and neurokinin B-induced bronchoconstriction with ID50 values of 0.13, 0.040 and 0.063 mg/kg (i.v.), respectively. CS-003 also inhibited capsaicin-induced bronchoconstriction (ID50: 0.27 mg/kg, i.v.), which is caused by endogenous neurokinins. CS-003 significantly inhibited citric acid-induced coughs and the effect was greater than those of other selective neurokinin receptor antagonists. CS-003 is a potent antagonist of triple neurokinin receptors and may achieve the best therapeutic efficacy on respiratory diseases associated with neurokinins compared to selective neurokinin receptor antagonists. (c) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:306 / 312
页数:7
相关论文
共 50 条
  • [21] Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro
    Wang, Xu
    Douglas, Steven D.
    Lai, Jian-Ping
    Tuluc, Florin
    Tebas, Pablo
    Ho, Wen-Zhe
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2007, 2 (01) : 42 - 48
  • [22] Neurokinin-1 Receptor Antagonist (Aprepitant) Inhibits Drug-Resistant HIV-1 Infection of Macrophages in vitro
    Xu Wang
    Steven D. Douglas
    Jian-Ping Lai
    Florin Tuluc
    Pablo Tebas
    Wen-Zhe Ho
    Journal of Neuroimmune Pharmacology, 2007, 2 : 42 - 48
  • [23] Behavioural and neurochemical changes induced by stress-related conditions are counteracted by the neurokinin-2 receptor antagonist saredutant
    Tamburella, Alessandra
    Leggio, Gian Marco
    Micale, Vincenzo
    Navarria, Andrea
    Bucolo, Claudio
    Cicirata, Valentina
    Drago, Filippo
    Salomone, Salvatore
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2013, 16 (04): : 813 - 823
  • [24] A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine
    Lördal, M
    Navalesi, G
    Theodorsson, E
    Maggi, CA
    Hellström, PM
    BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (01) : 215 - 223
  • [25] Neurokinin 1 receptor antagonist along with dexamethasone reduces the inflammation in COVID-19 patients: a novel therapeutic approach
    Mehboob, Riffat
    Ahmad, Fridoon Jawad
    Qayyum, Ahad
    Rana, Muhammad Asim
    Tariq, Muhammad Akram
    Tamur, Shadi
    Shahid, Imran
    Mirza, Iman M.
    Fathaddin, Amany
    Abusikkien, Samy A.
    Zayed, Mohamed A.
    ADVANCEMENTS IN LIFE SCIENCES, 2023, 10 (03): : 426 - 433
  • [26] Stereoselective synthesis of a novel 2-aza-7-oxabicyclo[3.3.0]octane as neurokinin-1 receptor antagonist
    Shishido, Yuji
    Ito, Fumitaka
    Morita, Hiromasa
    Ikunaka, Masaya
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (24) : 6887 - 6890
  • [27] Commentary on "Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men" Comment
    Abbara, Ali
    Phylactou, Maria
    Dhillo, Waljit S.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (02): : E1028 - E1030
  • [28] Aprepitant: A novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma
    Ladizinski, Barry
    Bazakas, Andrea
    Olsen, Elise A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 67 (05) : E197 - E198
  • [29] Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder
    Michelson, David
    Hargreaves, Richard
    Alexander, Robert
    Ceesay, Paulette
    Hietala, Jarmo
    Lines, Christopher
    Reines, Scott
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2013, 16 (01): : 1 - 11
  • [30] Neurokinin-1 receptor antagonist inhibits short-term sulfuric-acid-induced airway hyperresponsiveness in sensitized guinea pigs
    Teramoto, S
    Tanaka, H
    Kaneko, S
    Abe, S
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2000, 121 (01) : 53 - 56